Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors

Journal of Medical Virology

Volumn 62, Issue 3, 2000, Pages 299-307

  Yeo, Winnie ^a   Chan, Paul K S ^a   Zhong, Sheng ^a   Ho, Wing M ^a   Steinberg, Joyce L ^a   Tam, John S ^a   Hui, Pun ^a   Leung, Nancy W Y ^a   Zee, Benny ^a   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cytotoxic chemotherapy; Hepatitis B virus; Reactivation

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC HEPATITIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RISK FACTOR; VIRUS HEPATITIS; VIRUS REACTIVATION;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGE; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; VIRUS ACTIVATION;

DNA VIRUSES; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 0033804328     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0     Document Type: Article

References (53)

1. Lamivudine therapy in chemotherapy-induced reactivation of hepatitis B virus infection
2. Contrasting relations between suppressor-cell function and suppressor-cell number in chronic liver disease
3. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men
4. Acute liver decompensation on withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers
5. Recovery from life-threatening corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy
6. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants
7. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma
8. Re-evaluation of α-interferon treatment of chronic hepatitis B using polymerase chain reaction
9. Successful treatment of lamivudine for fulminant hepatitis B infection following intensive therapy for high grade non-Hodgkin's lymphoma
10. The clinical toxicity of anticancer drugs and its prediction
11. A preliminary trial of lamivudine for chconic hepatitis B infection
12. Inhibition of the replication of hepatitis B virus in vitro by (-)',3'-dideoxy-3'3thiacytidine, results in a rapid suppression of hepaviral DNA in sera
13. Mutations in the core nucleoside sequence of hepatitis B virus correlate with fulminant and severe hepatitis
14. Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy
15. Effects of immunosuppressive therapy with prednisolone on B and T cell function in patients with chronic type B hepatitis
16. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection
17. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy
18. Adoptive transfer of immunity to hepatitis B virus after T-cell depleted allogeneic bone marrow transplantation
19. Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan
20. A one-year trial of lamivudine for chronic hepatitis B
21. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation
22. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients
23. Hepatitis B infection in patients with lymphomas
24. Hepatitis B virus pre-core mutation and fulminant hepatitis in the United States
25. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem
26. Acute exacerbation in chronic type of B hepatitis: Comparison between HBeAg and antibody positive patients
27. Two years lamivudine in chronic hepatitis B infection: Results of a placebo-controlled multicentre study in Asia
28. Acute exacerbation in Chinese patients with chronic hepatitis B (HBV) infection: Incidence, predisposing factors and etiology
29. Continued histologic improvement in Chinese patients with chronic hepatitis B with 2 years lamivudine
30. Hepatitis B virus infection in Chinese families in Hong Kong
31. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study
32. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: Clinical course and possible treatment with ganciclovir
33. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis
34. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes
35. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987-1991
36. Mutations in the pre-core region of hepatitis B virus DNA in patients with fulminant and severe hepatitis
37. Effects of liver disease on drug metabolism
38. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen
39. A randomised, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment hepatitis B
40. Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations
41. Hepatotoxicity of chemotherapeutic agents
42. Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B
43. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection
44. New nucleoside analogues for chronic hepatitis B infection
45. Durability of HBeAg seroconversion after lamivudine therapy in controlled phase II and III trials
46. Hepatocellular carcinoma in Hong Kong: Clinical study of 340 cases
47. Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy
48. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role
49. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier
50. Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies
51. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy